Specimen and Data Collection in South Carolina Medicaid-Enrolled Patients With Type 2 Diabetes (T2D) and Metabolically Healthy Controls
Guardian Research Network, Inc. · with South Carolina Department of Health and Human Services, Spartanburg Regional Healthcare System · NCT07731399
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 40–70 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 1200
- US sites recruiting
- 2
- Study start
- August 2026
- Record last updated
- August 18, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The primary purpose of this study is to use multiomic data in combination with clinical assessments, electronic health records, cognitive and mood assessments, wearable technologies and lifestyle/behavioral data to identify data elements or combinations of data elements with strong positive or negative correlation to CKD diagnosis and/or progression in Type 2 Diabetes (T2D) patients. Achieving this aim will allow researchers and physicians to significantly improve the prediction of health trajectories of and formulate novel strategies to potentially prevent, treat or reverse T2D. South Carolina Medicaid-enrolled patients diagnosed with T2D and a smaller subset of non-T2D SC Medicaid patients may participate in this study. Participants who complete required procedures will be compensated for their time and transportation, may keep their study-provided Fitbit device to help maintain their healthcare improvement journey, and will have a personal Certified Diabetes Educator to consult and assist with managing their diabetes diagnosis.
Being studied: Not applicable- observational study
Conditions: Type 2 Diabetes; Healthy (Controls)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
INCLUSION CRITERIA
All Participants
- 40 to 70 years of age (inclusive) at enrollment
- Enrolled as Medicaid recipients
- Ability to provide informed consent and authorization for release of relevant protected health information or personal data
- Ability to provide a blood sample(s) of up to 70 mL and other required biospecimens, including genetic samples.
T2D Group:
- Current diagnosis of Type 2 diabetes OR a blood level of hemoglobin A1c equal to or greater than 6.5% at any time within the past 12 months
Control Group
- Blood level of hemoglobin A1c less than or equal to 5.6% at time of enrollment
- No diagnosis of Type 2 diabetes
EXCLUSION CRITERIA
- Pregnancy at time of enrollment (by self-report of pregnancy status)
- Lack of fluency in spoken and written English
- Type 1 diabetes or any other type of diabetes besides Type 2 diabetes
- Active cancer diagnosis or cancer that achieved complete remission within three (3) years prior to enrollment, other than non-melanoma skin cancer (e.g. malignant basal cell neoplasm of skin and/or squamous cell carcinoma of skin)
- Major Adverse Cardiovascular Events within two (2) years prior to enrollment
- Chronic Obstructive Pulmonary Disease
- Cognitive impairment or neurodegenerative diseases (e.g., Alzheimer's disease, dementia, multiple sclerosis, Parkinson's disease, etc.)
- Pancreatitis or other diseases of the pancreas (besides diabetes)
- The participant is, in the opinion of the investigator, unlikely to be able to complete all study requirements
Recruiting US locations
Clemson Health Clinic at Orangeburg
Orangeburg, SC 29118
Site contact: Katie Poplin · 864-656-4503 · kpoplin@clemson.edu
Clemson Health Clinic at Walhalla
Walhalla, SC 29691
Site contact: Katie Poplin · 864-656-4503 · kpoplin@clemson.edu
Similar studies in South Carolina
All diabetes studies in South Carolina →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Greer, SC + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Merck Sharp & Dohme LLC
- Location
- Bluffton, SC + 27 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Merck Sharp & Dohme LLC
- Location
- Aiken, SC + 18 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
Sonavex, Inc.
- Location
- Columbia, SC + 19 other US sites
- Eligibility basics
- Ages 18–84